Richard Blatter, DO
Urology · Idaho Falls, IDNPI 1154682565
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 97.3% of the total across 217 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 41 manufacturers reported payments, led by Boston Scientific at 24.0% of the total.
Across 217 payments — averaging $22.34 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Boston Scientific$1K
- Astellas Pharma US Inc$406
- Johnson & Johnson$397
- AbbVie$397
- Sumitomo Pharma America, Inc.$278
- Procept Biorobotics Corporation$235
- plus $2K from 35 others
What the payments were for
- Food & beverage$4,71997%
- Education$1293%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Boston Scientific | 33 | $1,165 |
| Astellas Pharma US Inc | 24 | $406 |
| Johnson & Johnson | 19 | $397 |
| AbbVie(2 entities) | 21 | $397 |
| Sumitomo Pharma America, Inc. | 13 | $278 |
| Procept Biorobotics Corporation | 5 | $235 |
| Calyxo, Inc. | 4 | $188 |
| Teleflex LLC | 9 | $177 |
| Pfizer | 8 | $139 |
| 180 Medical, Inc. | 5 | $111 |
| Myovant Sciences Inc. | 6 | $105 |
| Merck | 5 | $105 |
| Ferring Pharmaceuticals Inc. | 5 | $95 |
| Immunitybio, Inc. | 4 | $78 |
| Coloplast | 5 | $78 |
| Urovant Sciences Inc | 4 | $73 |
| Laborie Medical Technologies Corp. | 3 | $68 |
| Axonics, Inc. | 3 | $63 |
| Endo Pharmaceuticals Inc. | 5 | $61 |
| Olympus America Inc. | 2 | $53 |
| Dendreon Pharmaceuticals LLC | 3 | $51 |
| Antares Pharma, Inc. | 3 | $48 |
| Palette Life Sciences, Inc. | 2 | $48 |
| Verity Pharmaceuticals Inc. | 2 | $45 |
| Tolmar Pharmaceuticals, Inc. | 3 | $39 |
| Bayer | 2 | $39 |
| Telix Pharmaceuticals | 1 | $38 |
| Cook Medical LLC | 2 | $31 |
| Myriad Genetic Laboratories, Inc. | 2 | $29 |
| Isoray, Inc | 2 | $27 |
| Inspire Medical Systems, Inc. | 1 | $25 |
| AstraZeneca | 1 | $19 |
| Ambu Inc. | 1 | $18 |
| ABC Home Medical Supply, Inc. | 1 | $18 |
| Neotract Inc. | 1 | $18 |
| E.r. Squibb & Sons, L.L.C. | 1 | $17 |
| Tolmar, Inc. | 1 | $15 |
| Convatec Inc. | 1 | $15 |
| Urogen Pharma, Inc. | 1 | $14 |
| Endo USA, Inc. | 1 | $14 |
| Travere Therapeutics, Inc. | 2 | $9 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- SWISS LITHOCLAST TRILOGY$206
- LithoVue$103
How this compares
$4,848 in reported general payments places this provider in the 75th percentile of 55 urology providers in Idaho.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MyrbetriqMirabegron | 131 | $84,086 |
| GemtesaVibegron | 64 | $33,592 |
| Potassium Citrate ErPotassium Citrate | 67 | $8,718 |
| Tamsulosin Hcl | 670 | $5,345 |
| Finasteride | 184 | $1,645 |
| Fosfomycin Tromethamine | 13 | $1,606 |
| Estradiol | 19 | $1,520 |
| Oxybutynin Chloride ErOxybutynin Chloride | 122 | $1,131 |
| Testosterone Cypionate | 13 | $997 |
| Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst | 61 | $929 |
| Ciprofloxacin Hcl | 98 | $677 |
| Doxycycline Hyclate | 32 | $645 |
| Cephalexin | 88 | $415 |
| Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim | 43 | $237 |
| Naproxen | 144 | $203 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Astellas Pharma US IncMyrbetriq | $406 | $84,086131 claims |
| Sumitomo Pharma America, Inc.Gemtesa | $278 | $33,59264 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 55 urology providers in Idaho.
Other urology in Idaho Falls
- Jared ManwaringIdaho Falls$4K
- Timothy TaylorIdaho Falls$3K
- Duncan HarrisIdaho Falls$3K
- Roger TallIdaho Falls$7
- Peter CannonIdaho Falls$4
- Sean StroupBoise$93K
- Zachary GlaserTwin Falls$15K
- Wade MunceyMeridian$9K
- John GreerMeridian$8K
- Dawn KingMeridian$8K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.